- Home
- DPG vs ERAS Comparison
DPG vs ERAS Comparison
Compare DPG & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DPG
- ERAS
- Stock Information
- Founded
- DPG 2011
- ERAS 2018
- Country
- DPG United States
- ERAS United States
- Employees
- DPG N/A
- ERAS N/A
- Industry
- DPG Trusts Except Educational Religious and Charitable
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- DPG Finance
- ERAS Health Care
- Exchange
- DPG Nasdaq
- ERAS Nasdaq
- Market Cap
- DPG 465.2M
- ERAS 484.4M
- IPO Year
- DPG N/A
- ERAS 2021
- Fundamental
- Price
- DPG $12.79
- ERAS $1.60
- Analyst Decision
- DPG
- ERAS Strong Buy
- Analyst Count
- DPG 0
- ERAS 6
- Target Price
- DPG N/A
- ERAS $4.50
- AVG Volume (30 Days)
- DPG 150.1K
- ERAS 749.3K
- Earning Date
- DPG 01-01-0001
- ERAS 08-12-2025
- Dividend Yield
- DPG 9.09%
- ERAS N/A
- EPS Growth
- DPG N/A
- ERAS N/A
- EPS
- DPG N/A
- ERAS N/A
- Revenue
- DPG N/A
- ERAS N/A
- Revenue This Year
- DPG N/A
- ERAS N/A
- Revenue Next Year
- DPG N/A
- ERAS N/A
- P/E Ratio
- DPG N/A
- ERAS N/A
- Revenue Growth
- DPG N/A
- ERAS N/A
- 52 Week Low
- DPG $7.90
- ERAS $1.01
- 52 Week High
- DPG $13.58
- ERAS $3.31
- Technical
- Relative Strength Index (RSI)
- DPG 63.68
- ERAS 55.28
- Support Level
- DPG $12.60
- ERAS $1.44
- Resistance Level
- DPG $12.80
- ERAS $1.68
- Average True Range (ATR)
- DPG 0.11
- ERAS 0.11
- MACD
- DPG 0.00
- ERAS 0.00
- Stochastic Oscillator
- DPG 86.67
- ERAS 67.69
About DPG Duff & Phelps Utility and Infrastructure Fund Inc.
Duff & Phelps Utility & Infrastructure Fund Inc. is an investment fund. Its investment objective is to seek total return, resulting from a high level of current income, with an emphasis on providing tax-advantaged dividend income.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.